Abstract
Demographers expect the number of older persons to double to 86.7 million — or to 20.6% of the US population — by the year 2050. As has occurred over the past decade, the health care costs associated with older age are expected to steadily increase approximately 2% per year causing both a public health and personal burden. A key component to reducing health care costs and maintaining well-being in older persons is preserving physical function throughout the lifespan. The challenge to this objective is to combat the origin of the loss of physical function through treatment of chronic disease conditions. Another approach is to enhance physical function despite the occurrence of comorbid conditions through enhancement of the neuromuscular system. The neuromuscular system provides the necessary components for all locomotion, and is thus a logical choice for preventative therapies to target. This article will give a general overview of the models and risk factors that explain the development of physical disability.
Keywords: Aging, disability, activity limitations, physical ability, economic burden, age, impairement, disease, obesity, muscle
Current Aging Science
Title: Development of Physical Disability in Older Adults
Volume: 4 Issue: 3
Author(s): Todd Manini
Affiliation:
Keywords: Aging, disability, activity limitations, physical ability, economic burden, age, impairement, disease, obesity, muscle
Abstract: Demographers expect the number of older persons to double to 86.7 million — or to 20.6% of the US population — by the year 2050. As has occurred over the past decade, the health care costs associated with older age are expected to steadily increase approximately 2% per year causing both a public health and personal burden. A key component to reducing health care costs and maintaining well-being in older persons is preserving physical function throughout the lifespan. The challenge to this objective is to combat the origin of the loss of physical function through treatment of chronic disease conditions. Another approach is to enhance physical function despite the occurrence of comorbid conditions through enhancement of the neuromuscular system. The neuromuscular system provides the necessary components for all locomotion, and is thus a logical choice for preventative therapies to target. This article will give a general overview of the models and risk factors that explain the development of physical disability.
Export Options
About this article
Cite this article as:
Manini Todd, Development of Physical Disability in Older Adults, Current Aging Science 2011; 4 (3) . https://dx.doi.org/10.2174/1874609811104030184
DOI https://dx.doi.org/10.2174/1874609811104030184 |
Print ISSN 1874-6098 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-6128 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
PDE-5 Inhibitors for BPH-Associated LUTS
Current Drug Targets Targeting Gender Difference in the Introduction of New Drugs for Diabetes Mellitus and Metabolic Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Exploring the Potential of NO-Independent Stimulators and Activators of Soluble Guanylate Cyclase for the Medical Treatment of Erectile Dysfunction
Current Pharmaceutical Design Role of miRNAs in Muscle Stem Cell Biology: Proliferation, Differentiation and Death
Current Pharmaceutical Design Age-Related Pharmacokinetic and Pharmacodynamic Changes and Related Risk of Adverse Drug Reactions
Current Medicinal Chemistry Breast Cancer: Current Developments in Molecular Approaches to Diagnosis and Treatment
Recent Patents on Anti-Cancer Drug Discovery Update on Medical and Surgical Management of Intracerebral Hemorrhage
Reviews on Recent Clinical Trials EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a,GSK-3β, and β-Catenin to Foster Vascular Integrity during Experimental Diabetes
Current Neurovascular Research The Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway as a Therapeutic Target for the Treatment of Human Acute Myeloid Leukemia (AML)
Current Signal Transduction Therapy Topoisomerase Enzymes as Therapeutic Targets for Cancer Chemotherapy
Medicinal Chemistry Update on Cancer Related Issues of Mesenchymal Stem Cell-Based Therapies
Current Stem Cell Research & Therapy Novel Anti-Arrhythmic Drugs for Atrial Fibrillation Management
Current Vascular Pharmacology Interleukin-15 in Gene Therapy of Cancer
Current Gene Therapy Systemic DNA Damage Response and Metabolic Syndrome as a Premalignant State
Current Molecular Medicine Dabigatran: The Anticoagulant We have Long Expected?
Recent Patents on Cardiovascular Drug Discovery Future Perspectives in the Pharmacological Treatment of Atrial Fibrillation and Ventricular Arrhythmias in Heart Failure
Current Pharmaceutical Design Editorial [ Has the Time Come for a New Definition of Microalbuminuria? ]
Current Vascular Pharmacology Pharmacokinetics of Topical Ocular Drug Delivery: Potential Uses for the Treatment of Diseases of the Posterior Segment and Beyond
Current Drug Metabolism Isolation and Proteomic Characterization of Bacterial Extracellular Membrane Vesicles
Current Protein & Peptide Science In vivo Piroxicam Metabolites: Possible Source for Synthesis of Central Nervous System (CNS) Acting Depressants
Central Nervous System Agents in Medicinal Chemistry